# Effects of Dapagliflozin on Progression of Alport Syndrome

> **NCT06226896** · — · ACTIVE_NOT_RECRUITING · sponsor: **Nanjing University School of Medicine** · enrollment: 222 (actual)

## Conditions studied

- Alport Syndrome

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT06226896
- **Lead sponsor:** Nanjing University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226896, "Effects of Dapagliflozin on Progression of Alport Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06226896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*